Ironwood Pharmaceuticals (IRWD) appointed Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline who retired after a 30-year career in GI science. The change is a management/growth leadership update with limited direct financial impact implied by the release.
Ironwood Pharmaceuticals (IRWD) appointed Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline who retired after a 30-year career in GI science. The change is a management/growth leadership update with limited direct financial impact implied by the release.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.08
Ticker Sentiment
